Part I Diagnosis.- 1 Classification of adenocarcinoma of the lung - with a special reference to prognosis .- 2 Screening lung cancer with low dose CT combined with molecular markers.- 3 PET-CT, bio-imaging for predicting prognosis and response to chemotherapy in patients with lung cancer.- 4 Methods in molecular diagnosis.- 5 Accurate nodal staging and biomarker testing with endobronchial ultrasound-guided transbronchial needle aspiration.- 6 Next generation sequencing and bioinformatics.- 7 Companion Diagnostics.

- Part II Treatment.- 8 Small cell lung cancer and molecular targeted therapy.- 9 Locally advanced non-small cell lung cancer and molecular targeted therapy.- 10 EGFR mutant.- 11 ALK mutant.- 12 Minor-driver mutant.- 13 Mechanism of resistance to targeted molecular therapy.- 14 Immunotherapy.

- 15 Lung cancer complicated with interstitial lung diseases.- 16 Management of adverse effects by molecular targeted therapy and immunotherapy.- Part III Evaluation.- 17 Health related-quality of life in molecular targeted therapy.- 18 Gene signature.- Part IV Novel approach.- 19 Targeting epithelial-mesenchymal transition and cancer stem cell- 20 Targeting the Lung Cancer Microenvironment: Harnessing Host Responses.